Annual Decline in Pentraxin 3 Is a Risk of Vascular Access Troubles in Hemodialysis Patients
Pentraxin 3 (PTX3), a multifunctional modulator of the innate immunoinflammatory response, is higher in patients undergoing hemodialysis than healthy control. Our study focused on annual change in PTX3 levels in patients with chronic hemodialysis, because regularly undergoing hemodialysis for many y...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2014/297954 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561333314256896 |
|---|---|
| author | Kei Nagai Atsushi Ueda Chie Saito Asako Zempo-Miyaki Kunihiro Yamagata |
| author_facet | Kei Nagai Atsushi Ueda Chie Saito Asako Zempo-Miyaki Kunihiro Yamagata |
| author_sort | Kei Nagai |
| collection | DOAJ |
| description | Pentraxin 3 (PTX3), a multifunctional modulator of the innate immunoinflammatory response, is higher in patients undergoing hemodialysis than healthy control. Our study focused on annual change in PTX3 levels in patients with chronic hemodialysis, because regularly undergoing hemodialysis for many years modifies vascular inflammatory status. To demonstrate whether annual change in PTX3 is associated with vascular events, we measured blood levels of pentraxins (PTX3 and high-sensitivity C-reactive protein (hsCRP)) at baseline and in the next year in 76 hemodialysis patients and observed 20 patients with vascular access troubles during follow-up years. The annual decline in PTX3, but not hsCRP, is a significant risk of the incidence of vascular access trouble that is a critical and specific complication for hemodialysis patients (hazard ratio; 0.732 per +1 ng/mL/year in PTX3, *P=0.039). This study is the first to focus on the annual change of pentraxins in a hemodialysis cohort. |
| format | Article |
| id | doaj-art-0637224eb77f45c6b11430b47edaa97e |
| institution | Kabale University |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-0637224eb77f45c6b11430b47edaa97e2025-02-03T01:25:20ZengWileyInternational Journal of Nephrology2090-214X2090-21582014-01-01201410.1155/2014/297954297954Annual Decline in Pentraxin 3 Is a Risk of Vascular Access Troubles in Hemodialysis PatientsKei Nagai0Atsushi Ueda1Chie Saito2Asako Zempo-Miyaki3Kunihiro Yamagata4Department of Nephrology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, JapanTsukuba University Hospital Hitachi Medical Education and Research Center, Jonan-cho 2-1-1, Hitachi, Ibaraki 317-0077, JapanDepartment of Nephrology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, JapanComprehensive Human Sciences, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, JapanDepartment of Nephrology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, JapanPentraxin 3 (PTX3), a multifunctional modulator of the innate immunoinflammatory response, is higher in patients undergoing hemodialysis than healthy control. Our study focused on annual change in PTX3 levels in patients with chronic hemodialysis, because regularly undergoing hemodialysis for many years modifies vascular inflammatory status. To demonstrate whether annual change in PTX3 is associated with vascular events, we measured blood levels of pentraxins (PTX3 and high-sensitivity C-reactive protein (hsCRP)) at baseline and in the next year in 76 hemodialysis patients and observed 20 patients with vascular access troubles during follow-up years. The annual decline in PTX3, but not hsCRP, is a significant risk of the incidence of vascular access trouble that is a critical and specific complication for hemodialysis patients (hazard ratio; 0.732 per +1 ng/mL/year in PTX3, *P=0.039). This study is the first to focus on the annual change of pentraxins in a hemodialysis cohort.http://dx.doi.org/10.1155/2014/297954 |
| spellingShingle | Kei Nagai Atsushi Ueda Chie Saito Asako Zempo-Miyaki Kunihiro Yamagata Annual Decline in Pentraxin 3 Is a Risk of Vascular Access Troubles in Hemodialysis Patients International Journal of Nephrology |
| title | Annual Decline in Pentraxin 3 Is a Risk of Vascular Access Troubles in Hemodialysis Patients |
| title_full | Annual Decline in Pentraxin 3 Is a Risk of Vascular Access Troubles in Hemodialysis Patients |
| title_fullStr | Annual Decline in Pentraxin 3 Is a Risk of Vascular Access Troubles in Hemodialysis Patients |
| title_full_unstemmed | Annual Decline in Pentraxin 3 Is a Risk of Vascular Access Troubles in Hemodialysis Patients |
| title_short | Annual Decline in Pentraxin 3 Is a Risk of Vascular Access Troubles in Hemodialysis Patients |
| title_sort | annual decline in pentraxin 3 is a risk of vascular access troubles in hemodialysis patients |
| url | http://dx.doi.org/10.1155/2014/297954 |
| work_keys_str_mv | AT keinagai annualdeclineinpentraxin3isariskofvascularaccesstroublesinhemodialysispatients AT atsushiueda annualdeclineinpentraxin3isariskofvascularaccesstroublesinhemodialysispatients AT chiesaito annualdeclineinpentraxin3isariskofvascularaccesstroublesinhemodialysispatients AT asakozempomiyaki annualdeclineinpentraxin3isariskofvascularaccesstroublesinhemodialysispatients AT kunihiroyamagata annualdeclineinpentraxin3isariskofvascularaccesstroublesinhemodialysispatients |